Highlights:
- Expects to become cash flow positive in Q416 and profitable in Q117
- Expects 2016 revenues to increase by at least 100% over 2015
- Company to announce new business model will significantly improve gross margins and earnings going
forward
- CannaDxTM, as standalone business, generating earnings and nearly $1 million in revenue since
commercialization in Q315
- Company’s proprietary data positions MyDx to enter into biopharmaceutical industry
- Company’s new business model supported by strengthened balance sheet and positive earnings key to driving shareholder
value in 2017 and beyond
LA JOLLA, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- MyDx, Inc. (OTCQB:MYDX), a rapidly growing chemical detection company, today
issued the following Special Letter to Shareholders from its Chairman and Chief Executive Officer Daniel Yazbeck.
“Dear Fellow Shareholders,
Before discussing our financial and operational outlook and the impact of this week’s passage of marijuana legalization across
eight states, I will first update the goals we set in our June 7, 2016 Shareholder Letter.
MyDx: Meeting 2016 Goals
In that Letter, we outlined three key goals:
New Product Launches. We are now accepting orders for our new OrganaDxTM and AquaDxTM Single Use Sensors – both of which launched and began limited shipping last
month in response to the water crises across the nation.
AquaDxTM tests water for various toxins and heavy metals. The recent Flint, Michigan, Alabama and Tampa, Florida water crises have demonstrated that consumers in
many cases must rely on themselves to ensure the safety of their water supply. Exemplifying our commitment to be a good corporate
citizen, we have shipped some of our early, AquaDx sensor inventory to those area residents affected and their
local media at no cost. Analysts forecast the global addressable market for water testing and analysis
instruments to be approximately $2.9 billion, and projected to grow at a compound annual growth rate of 5.2% to reach $3.5 billion
by 2019.
OrganaDxTM tests fruits and vegetables, as well as cannabis (including popular vape oils and edibles) for pesticides
and heavy metals. While cannabis distribution is highly regulated, its safety is not. This should be a major concern to both the
industry and the end consumer since pesticides are typically found in much higher concentrations in cannabis than other
crops. However, with this week’s passage of new cannabis initiatives, we expect the demand for cannabis testing, hence the
need for OrganaDx, will increase dramatically.
AeroDxTM is entering beta testing shortly in advance of its entry into commercialization in early 2017. Based on the
industry’s overwhelming acceptance of our latest sensors, we believe AeroDx will prove to be yet another successful MyDx product
line that will immediately contribute to both top and bottom line.
Market Penetration. The market’s adoption of our CannaDx product is a testament to the proprietary technology
and innovative approach to testing and tracking we have taken at MyDx. CannaDx continues to capture market share with growers, at
legal marijuana dispensaries and hydroponic equipment shops internationally, as well as direct consumers of cannabis products
through our online shop and our growing global distribution network.
Earnings Growth. CannaDx, as a standalone business, is generating earnings and nearly $1 million in revenues
since commercialization in Q315. As we have been projecting since the first half of 2016, we expect to become cash flow positive in
the current, fourth quarter. Additionally, I will take this opportunity to provide our shareholders with guidance that we expect
revenues for our 2016 fiscal year, ending December 31, will increase by at least 100% year-over-year.
Passage of Cannabis Initiatives to Expand MyDx Market Size
On November 8, 2016, America sent two clear messages to the world. Donald Trump will be our new President, and marijuana is here to
stay. Cannabis is now legal for adults 21 and over in eight states and the District of Columbia. More than half of all states, 28
in total after Tuesday, allow cannabis for medicinal use. Along with a proliferation of consumers and dispensaries, this will drive
an increasing number of home growers as well as far more biopharmaceutical R&D investment into cannabis leading to important
new medical breakthroughs.
Ultimately, the cannabis industry will evolve to a level of maturation comparable with the regulated beer and
wine markets. Cannabis will become a commodity, so product differentiation will have to come in the form of superior
marketing and branding, as well as word-of-mouth adoption of products that can actually deliver a desired feeling or ailment
relief, and are free from pesticides.
MyDx offers consumers the first and only handheld chemical analyzer that tests the safety and chemical profile
of cannabis samples, associates them with a feeling and ailment relief, and helps people find a safe strain that works for
them. We are very well positioned to support and capitalize on this movement as our products and markets evolve.
CannaDx Data to Drive Entry into Biopharmaceutical Industry
Major pharmaceutical companies such as Novartis, Pfizer and Roche need to discover, develop and formulate new drugs that must
undergo stringent FDA clinical trials which cost on average nearly $300 million. Our CannaDx application, which is HIPAA compliant,
collects users’ test data which then can be used to guide cannabis-based drug discovery. MyDx has accumulated over 30,000 unique
data points that can significantly accelerate any pharmaceutical company seeking to discover new cannabis-based drugs. We believe
this asset alone has more potential than all of our other product lines combined.
In Summary
While not unusual for a young public company’s stock, the past few weeks have been quite a roller coaster. I, as one of the
Company’s largest shareholders, and everyone else working for you here at MyDx, feel your concern and are all the more grateful for
your support. Although we might continue to experience some additional pressure from outstanding convertible debentures, I am
confident the worst of that turbulence is now behind us and this negative pressure will be offset by a number of positive
developments that we have been diligently pursuing over the past year.
These latest developments, when announced, coupled with our stronger financial position will support our outlook for
substantially increasing revenue and earnings in 2017 and beyond.
Sincerely,
/s/
Daniel R. Yazbeck
Chairman and Chief Executive Officer
MyDx, Inc.”
About MyDx, Inc.
MyDx, Inc. (OTCQB:MYDX) is a chemical detection and sensor technology company based in San
Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company
developed MyDx®, a patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm
of the user’s hand. The multi-use MyDx analyzer leverages over a decade of established chemical detection technology to measure
chemicals of interest. The Company owns a substantial and growing intellectual property portfolio of patents covering its
technology. The MyDx CannaDxTM, AquaDxTM and OrganaDxTM sensors are now commercialized, and the
AeroDxTM application is next in line. All Sensors will be compatible with a MyDx App that empowers consumers to test the
chemical composition of what they eat, drink and inhale. For more information, please visit www.cdxlife.com.
Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of
1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain
forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other
statements relating to future operations and results. Any statements in this press release that are not statements of historical
fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate,"
"estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking
statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and
uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing
requirements, development of new products, our ability to complete our product testing and launch our product commercially, the
acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of
competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from
time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.
Investor Contact: Phillip Sugarman, Vice President Investor Relations Partners Phone: 818-280-6800 psugarman@irpartnersinc.com
